Sangamo Therapeutics (SGMOQ) Capital Expenditures (2010 - 2025)

Sangamo Therapeutics' Capital Expenditures history runs 16 years deep, the most recent figure standing at $14000.0 for Q4 2025.

• On a quarterly basis, Capital Expenditures rose 109.15% year-over-year to $14000.0 in Q4 2025; TTM through Dec 2025 was $102000.0, a 56.78% decrease from a year earlier, with the FY2025 full-year figure at $102000.0, down 56.78% from the prior year.
• Capital Expenditures retreated to $14000.0 in Q4 2025 per SGMOQ's latest filing, from $64000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $12.3 million in Q2 2021 and bottomed at -$5.3 million in Q2 2023.
• The 5-year median for Capital Expenditures is $311500.0 (2024), against an average of $2.2 million.
• Biggest YoY gain for Capital Expenditures was 351.93% in 2023; the steepest drop was 21064.0% in 2023.
• Year by year, Capital Expenditures stood at $2.9 million in 2021, then jumped by 161.51% to $7.5 million in 2022, then slumped by 130.91% to -$2.3 million in 2023, then jumped by 93.38% to -$153000.0 in 2024, then jumped by 109.15% to $14000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Capital Expenditures figures stand at $14000.0 (Q4 2025), $64000.0 (Q3 2025), and -$210000.0 (Q2 2025).